Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
Department of Molecular Oncology, BC Cancer Agency, Vancouver, BC, Canada.
J Pathol. 2022 Dec;258(4):325-338. doi: 10.1002/path.6006. Epub 2022 Oct 14.
Clear cell ovarian carcinoma (CCOC) is the second most common subtype of epithelial ovarian carcinoma. Late-stage CCOC is not responsive to gold-standard chemotherapy and results in suboptimal outcomes for patients. In-depth molecular insight is urgently needed to stratify the disease and drive therapeutic development. We conducted global proteomics for 192 cases of CCOC and compared these with other epithelial ovarian carcinoma subtypes. Our results showed distinct proteomic differences in CCOC compared with other epithelial ovarian cancer subtypes including alterations in lipid and purine metabolism pathways. Furthermore, we report potential clinically significant proteomic subgroups within CCOC, suggesting the biologic plausibility of stratified treatment for this cancer. Taken together, our results provide a comprehensive understanding of the CCOC proteomic landscape to facilitate future understanding and research of this disease. © 2022 The Pathological Society of Great Britain and Ireland.
透明细胞卵巢癌（CCOC）是上皮性卵巢癌的第二大常见亚型。晚期 CCOC 对金标准化疗无反应，导致患者预后不佳。深入的分子见解对于疾病分层和推动治疗发展至关重要。我们对 192 例 CCOC 进行了全球蛋白质组学研究，并将这些结果与其他上皮性卵巢癌亚型进行了比较。我们的结果表明，与其他上皮性卵巢癌亚型相比，CCOC 存在明显的蛋白质组学差异，包括脂质和嘌呤代谢途径的改变。此外，我们报告了 CCOC 中潜在的具有临床意义的蛋白质组亚组，这表明对这种癌症进行分层治疗具有生物学上的合理性。总之，我们的研究结果提供了对 CCOC 蛋白质组景观的全面了解，有助于未来对这种疾病的理解和研究。
